A041202 CLL

Leukemia

A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib alone in untreated older patients with Chronic Lymphocytic Leukemia (CLL)

Key Team Members

Principal Investigator

Asheesh Lal, MD

Research Coordinator

Selena Lollar

Not Accepting Patients

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease.